• About Cannabis Science

Dr. Robert Melamede, Ph.D.Dr. Robert Melamede, Ph.D.  - Cannabis Science President Emeritus
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

 

Dr. Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc.
Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world. He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent.

Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.

Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.

Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.

 

Dr. Michael J. Goldblatt
Dr. Goldblatt, the Former Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), holds extensive experience in successfully pioneering next-generation technologies, including host-oriented therapeutics for infectious disease.  He received his B.A. in Biology from Reed College and his Ph.D. and J.D. from the University of California-Davis and is admitted to practice law in New York and Washington, D.C. and with the United States Patent Bar.

Dr. Goldblatt is also the President and CEO of Functional Genetics, a privately held biotechnology Company founded in 2001 (www.functional-genetics.com). Functional Genetics focuses on the development of new antibody-based therapeutics to prevent and treat a broad spectrum of viruses including HIV, Herpes, and respiratory illnesses. Functional Genetics' leading candidate FGI-101-1A6 is a fully human monoclonal antibody which targets and eliminates cells that have been infected by various viruses including HIV-1 and influenza. FGI-101-1A6 has successfully completed its Phase IA clinical trial.

Dr. Goldblatt has over 20 years of experience working in biotechnology, product development, and regulatory affairs. He served as the Science and Technology Officer at McDonald's Corporation and Director of Scientific and Regulatory Affairs at General Foods Corporation. Dr. Goldblatt has extensive knowledge and experience in the identification and commercial development of early stage technologies.

 

Dr. Alan Shackelford
Dr. Alan Shackelford is a graduate of the University of Heidelberg School of Medicine in Heidelberg, Germany and completed his postgraduate medical training at major teaching hospitals of the Harvard Medical School, including a residency in internal medicine and clinical Fellowships in nutritional and behavioral medicine as well as a Harvard Medical School research fellowship.

Dr. Shackelford’s interests are wide-ranging, and include the investigation and study of the medical uses of cannabis as well as applying principles of behavioral medicine to the treatment of stress-related illnesses, obesity, insomnia and tobacco dependence.

He has advised legislators in Colorado and Connecticut on the medical uses of cannabis during deliberations on bills establishing and regulating medical use of cannabis, has testified a number of times before state senate and house committees in Colorado and Connecticut on the medical uses of marijuana and serves on the Colorado Department of Revenue Medical Marijuana Advisory Work Group and a similar group advising the City and County of Denver. Dr. Shackelford is principle physician of Amarimed of Colorado, a medical practice devoted to the study and evaluation of cannabis as a medical treatment option.

 

Dr. William L. Courtney
Dr. William Courtney, in addition to holding a B.S. in Microbiology and M.D. degree, has a Post Doctorate in Forensic Examination and Forensic Medicine. He is a member of the International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney teaches Continuing Medical Education (CME) courses in clinical cannabis, and a Survey Course on Endogenous Cannabinoid System, and hosted the Second International CB2 Conference in California.

 

Dr. J. Thomas August
Dr. August’s distinguished career in clinical research directed at the molecular biology and protein structure of RNA viruses, and clinical exploration of human immunology has positioned him as a leading authority on human immune response mechanisms.

Dr. August currently holds the positions of a University Distinguished Service Professor of Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine, Professor of Medicine, National University of Singapore; and Professor, Perdana University Graduate School of Medicine, Malaysia.

Dr. August has been involved with the development of a new generation of HIV vaccines and the protein antigenic structure of leading viral pathogens, including HIV-1, influenza, and other pathogens including dengue and West Nile viruses. His numerous publications are reflective of scientific commercial enterprises in cancer and HIV.

 

Dr. Ritchard L. Fishman
Dr. Fishman established his practice in 1961, and since then has been seeing patients of all ages for Diabetes, Hypertension, Weight Loss, Arthritis, Pain Management and many other medical problems. Dr. Fishman is widely recognized as a leader in the research in these fields. Since 1998, Dr. Fishman has been involved in clinical trials for medications, treatments, devices and vaccines for major pharmaceutical companies seeking FDA approval. Dr. Fishman is also a Chairman of the New Life Diabetes Center’s Medical Review Board and is responsible for reviewing all medical operations supervised by this Center. Dr. Fishman graduated Ohio State University in 1953 where he earned a Bachelor of Science degree with a Major in Biology. He also received his Medical Doctor degree from Ohio State University in 1957. Dr. Fishman has professional affiliations with the Downey Community Hospital, Whittier Presbyterian Hospital, and Whittier Hospital. Also, he has been a guest lecturer with the Western University School of Osteopathic Medicine and Senior Medical advisor for New Life Diabetic Centers in California and Nevada.

 

Dr. Michael McGrath, MD, Ph.D.
Dr. Michael McGrath is co-founder of Pathologica LLC and Neuraltus Pharmaceuticals, both privately held companies involved in developing therapeutic approaches for the treatment of various chronic diseases. Pathologica is developing a novel approach to the treatment of HIV disease, its lead drug candidate, PA-300, targeting HIV reservoirs in macrophages implicated as a cause of HIV related neurologic disease, cardiovascular disease and various forms of cancer. UCSF and Pathologica received approximately $10M from the NIH to perform all of the preclinical studies required by the FDA for administering PA300 to humans, with clinical trials targeted to begin in 2013. Dr. McGrath and colleagues raised $17M in 2009 to fund Neuraltus' phase 2 clinical trial in patients with amyotrophic lateral sclerosis using NP001 in early 2013, the first macrophage targeted approach for Lou Gehrig's disease.

Dr. McGrath maintains an extensive resume spanning more than three decades with a strong focus on HIV and oncology. Dr. McGrath's career in HIV began early in the HIV epidemic as Assistant Professor of Medicine, AIDS/Oncology Division, University of California, San Francisco/San Francisco General Hospital in 1985. In the same year he began serving as an ad hoc grant reviewer for the NIMH, NCI, NIAID and the VA and joined the Scientific Advisory Board for The American Foundation for AIDS Research (AmFAR) where he continues to serve.

Since joining the staff of the UCSF in 1985, Dr. McGrath has held numerous positions at USCF including Assistant Professor of Laboratory Medicine UCSF/SFGH, Associate Professor of Laboratory Medicine and Medicine UCSF/SFGH and Associate Professor of Pathology UCSF/SFGH.

Dr. McGrath earned his Bachelor's of Science (BS) at the University of Minnesota in 1974 in Biology. He obtained his Medical degree (MD) in 1980 at Stanford University School of Medicine and his PhD in Cancer Biology in 1985 at Stanford University School of Medicine.

 

Dr. Harold C. Smith, Ph.D.
Dr. Harold C. Smith, Ph.D., Professor in Biochemistry, Biophysics, and Oncology with secondary appointments as Professor in the Department of Genetics and Pathology and a Member of the Center for RNA Biology at the University of Rochester, School of Dentistry and Medicine, to the Company's Scientific Advisory Board. At the University of Rochester Dr. Smith directs a research laboratory and teaches undergraduate and medical school courses in biochemistry. He is a member of the RNA Society and a member of the American Association for the Advancement of Science. He received the SUNY at Buffalo's Distinguished Alumni Award as well as several awards from the University or Rochester for contributions to the teaching mission and leadership in mentoring. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith has also been the recipient of a number of grants, including grants from the Bill and Melinda Gates Foundation, the NIH, the United States Air Force, and the Office of Naval Research. In total, Dr. Smith has received federal and foundation research grants in excess of $6.5 million. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith is the author of more than 100 peer-reviewed manuscripts and reviews during his career, exceeding more than 9,973 citations.

Dr. Smith received his Ph.D. from SUNY at Buffalo, following BS and MS degrees from Purdue University and an MA degree from SUNY at Buffalo. Dr. Smith also held post-doctoral positions in biochemistry at SUNY at Buffalo followed by three post-doctoral positions in biochemistry, pharmacology, and medical genetics, respectively, at Baylor College of Medicine.

In addition, Dr. Smith is the Founder and CEO of OyaGen, Inc., a biotech company in Rochester, New York developing novel therapeutics for infectious disease and cancer. OyaGen has raised in excess of $4 million from venture and angel investor sources and two federal grants for assay development.

Connect With Us


Facebook  Twitter  This email address is being protected from spambots. You need JavaScript enabled to view it. Go to USTREAM

People Behind the Scenes

Dr. Robert Melamede, Ph.D.
"The endocannabinoid system provides unique opportunities for regulating homeostasis to promote health with phyto-cannabinoid based pharmaceuticals."
Meet Dr. Robert Melamede, Ph.D. >